Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tanya Siddiqi, Paul Frankel, Jan H. Beumer, Brian F. Kiesel, Susan Christner, Chris Ruel, Joo Y. Song, Robert Chen, Kevin R. Kelly, Sikander Ailawadhi, Paul Kaesberg, Leslie Popplewell, Sandrine Puverel, Richard Piekarz, Stephen J. Forman & Edward M. Newman. (2020) Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leukemia & Lymphoma 61:2, pages 309-317.
Read now
Read now
Daniel R Premkumar, Esther P Jane & Ian F Pollack. (2015) Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells. Cancer Biology & Therapy 16:2, pages 233-243.
Read now
Read now
Articles from other publishers (42)
Roberta Cacioppo & Catherine Lindon. (2022) Regulating the regulator: a survey of mechanisms from transcription to translation controlling expression of mammalian cell cycle kinase Aurora A. Open Biology 12:9.
Crossref
Crossref
Michèle J. Hoffmann, Sarah Meneceur, Katrin Hommel, Wolfgang A. Schulz & Günter Niegisch. (2021) Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells. Genes 12:2, pages 260.
Crossref
Crossref
Sandeepraj Pusalkar, Xiaofei Zhou, Yuexian Li, Lawrence Cohen, Jun Johnny Yang, Suresh K. Balani, Cindy Xia, Wen Chyi Shyu, Chuang Lu, Karthik Venkatakrishnan & Swapan K. Chowdhury. (2020)
Biotransformation Pathways and Metabolite Profiles of Oral [
14
C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
. Drug Metabolism and Disposition 48:3, pages 217-229.
Crossref
Crossref
Faria Sultana, Kesari Lakshmi Manasa, Siddiq Pasha Shaik, Srinivasa Reddy Bonam & Ahmed Kamal. (2020) Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Current Medicinal Chemistry 26:40, pages 7212-7280.
Crossref
Crossref
Xiaofei Zhou, Sandeepraj Pusalkar, Swapan K. Chowdhury, Shawn Searle, Yuexian Li, Claudio Dansky Ullmann & Karthik Venkatakrishnan. (2018) Mass balance, routes of excretion, and pharmacokinetics of investigational oral [14C]-alisertib (MLN8237), an Aurora A kinase inhibitor in patients with advanced solid tumors. Investigational New Drugs 37:4, pages 666-673.
Crossref
Crossref
Aline A Zuma & Wanderley de Souza. (2018) Histone deacetylases as targets for antitrypanosomal drugs. Future Science OA 4:8, pages FSO325.
Crossref
Crossref
Marjorie G. Zauderer. 2017. Asbestos and Mesothelioma. Asbestos and Mesothelioma
313
345
.
Kislay RoyDrDr, Bhasker Sriramoju, Rupinder K. KanwarPhDPhD & Jagat R. Kanwar. (2016) Ophthalmic Combination of SurR9-C84A and Trichostatin-A Targeting Molecular Pathogenesis of Alkali Burn. Frontiers in Pharmacology 7.
Crossref
Crossref
Thi Thuy Duong Le, Phuong Thu Ha, Thi Hai Yen Tran, Dac Tu Nguyen, Hoai Nam Nguyen, Van Khanh Bui & My Nhung Hoang. (2016)
In vitro
evaluation of Aurora kinase inhibitor—VX680—in formulation of PLA-TPGS nanoparticles
. Advances in Natural Sciences: Nanoscience and Nanotechnology 7:2, pages 025010.
Crossref
Crossref
Bryan J. Schneider & Gregory P. Kalemkerian. 2016. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
149
174
.
Gerald S. Falchook, Christel C. Bastida & Razelle Kurzrock. (2015) Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. Seminars in Oncology 42:6, pages 832-848.
Crossref
Crossref
Sung-Keum Seo, Chang-Sun Hwang, Tae-Boo Choe, Seok-Il Hong, Jae Youn Yi, Sang-Gu Hwang, Hyun-Gyu Lee, Sang Taek Oh, Yun-Han Lee & In-Chul Park. (2014) Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation. Oncotarget 6:28, pages 26528-26540.
Crossref
Crossref
Huifeng Niu, Mark Manfredi & Jeffrey A. Ecsedy. (2015) Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer. Frontiers in Oncology 5.
Crossref
Crossref
Karthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, Lim Soon Thye, Wee Joo Chng, Brigette Ma, Ming Huang Chen, Xiaofei Zhou, Hua Liu, Virginia Kelly & Won Seog Kim. (2015) Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. Investigational New Drugs 33:4, pages 942-953.
Crossref
Crossref
Jong Kyu Woo, Ju-Hee Kang, DongYun Shin, Seong-Hyeok Park, Kyungsu Kang, Chu Won Nho, Je Kyung Seong, Sang-Jin Lee & Seung Hyun Oh. (2015) Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression. Molecular Cancer Therapeutics 14:7, pages 1693-1704.
Crossref
Crossref
Anderly C. ChuehJanson W.T. TseLars TögelJohn M. Mariadason. (2015) Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells. Antioxidants & Redox Signaling 23:1, pages 66-84.
Crossref
Crossref
Namita Chatterjee & Martin Tenniswood. (2015) The potential of histone deacetylase inhibitors in breast cancer therapy. Breast Cancer Management 4:2, pages 85-97.
Crossref
Crossref
Gerald Falchook, Razelle Kurzrock, Launce Gouw, David Hong, Kimberly A. McGregor, Xiaofei Zhou, Hongliang Shi, Howard Fingert & Sunil Sharma. (2014) Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. Investigational New Drugs 32:6, pages 1181-1187.
Crossref
Crossref
RUCHENG YAO, JUN ZHENG, WEIHONG ZHENG, YUAN GONG, WEI LIU & RONGCHUN XING. (2014) VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin. Oncology Letters 7:1, pages 121-124.
Crossref
Crossref
Wei-Feng Song, Lei Wang, Wei-Yi Huang, Xun Cai, Jiu-Jie Cui & Li-Wei Wang. (2013) MiR-21 Upregulation Induced by Promoter Zone Histone Acetylation is Associated with Chemoresistance to Gemcitabine and Enhanced Malignancy of Pancreatic Cancer Cells. Asian Pacific Journal of Cancer Prevention 14:12, pages 7529-7536.
Crossref
Crossref
Chi-qi Chen, Cheng-shui Chen, Jun-jie Chen, Lian-ping Zhou, Hong-lei Xu, Wei-wei Jin, Jian-bo Wu & Shen-meng Gao. (2013) Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Molecular and Cellular Biochemistry 383:1-2, pages 137-148.
Crossref
Crossref
Ranee Mehra, Ilya G Serebriiskii, Barbara Burtness, Igor Astsaturov & Erica A Golemis. (2013) Aurora kinases in head and neck cancer. The Lancet Oncology 14:10, pages e425-e435.
Crossref
Crossref
Jodi A. Muscal, Kathleen A. Scorsone, Linna Zhang, Jeffrey A. Ecsedy & Stacey L. Berg. (2012) Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Investigational New Drugs 31:1, pages 39-45.
Crossref
Crossref
E. Claire Dees, Roger B. Cohen, Margaret von Mehren, Thomas E. Stinchcombe, Hua Liu, Karthik Venkatakrishnan, Mark Manfredi, Howard Fingert, Howard A. BurrisIIIIII & Jeffrey R. Infante. (2012) Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations. Clinical Cancer Research 18:17, pages 4775-4784.
Crossref
Crossref
Andres Cervantes, Elena Elez, Desamparados Roda, Jeffrey Ecsedy, Teresa Macarulla, Karthik Venkatakrishnan, Susana Roselló, Jordi Andreu, JungAh Jung, Juan Manuel Sanchis-Garcia, Adelaida Piera, Inma Blasco, Laura Maños, José-Alejandro Pérez-Fidalgo, Howard Fingert, Jose Baselga & Josep Tabernero. (2012) Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research 18:17, pages 4764-4774.
Crossref
Crossref
Carmela Dell'Aversana, Ilaria Lepore & Lucia Altucci. (2012) HDAC modulation and cell death in the clinic. Experimental Cell Research 318:11, pages 1229-1244.
Crossref
Crossref
Shan Zhu, Yueyang Li, Li Zhao, Pingfu Hou, Chenyan Shangguan, Ruosi Yao, Weina Zhang, Yu Zhang, Jiang Tan, Baiqu Huang & Jun Lu. (2012) TSA-induced JMJD2B downregulation is associated with cyclin B1-dependent survivin degradation and apoptosis in LNCap cells. Journal of Cellular Biochemistry 113:7, pages 2375-2382.
Crossref
Crossref
Teena BhatlaJinhua WangDebra J. MorrisonElizabeth A. RaetzMichael J. Burke, Patrick Brown & William L. Carroll. (2012) Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 119:22, pages 5201-5210.
Crossref
Crossref
Hee Jeong Lee, Eun Suk Koh, Jeong Ja Kwak, Hee Kyung Kim, Sang‐Mo Park & In‐Ho Choi. (2012) Clinicopathologic significance of Aurora kinase A expression in non‐small cell lung cancer. Basic and Applied Pathology 5:1, pages 8-14.
Crossref
Crossref
Kleiton Silva Borges, Angel Maurício Castro-Gamero, Daniel Antunes Moreno, Vanessa da Silva Silveira, Maria Sol Brassesco, Rosane Gomes de Paula Queiroz, Harley Francisco de Oliveira, Carlos Gilberto CarlottiJr.Jr., Carlos Alberto Scrideli & Luiz Gonzaga Tone. (2011) Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. Journal of Cancer Research and Clinical Oncology 138:3, pages 405-414.
Crossref
Crossref
Ya-Fen Hsu, Joen-Rong Sheu, Chien-Huang Lin, De-Shin Yang, George Hsiao, George Ou, Pei-Ting Chiu, Yu-Han Huang, Wen-Hsin Kuo & Ming-Jen Hsu. (2012) Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1820:2, pages 104-115.
Crossref
Crossref
Lei Zhang, Guiying Wang, Lin Wang, Chenlin Song, Ye Leng, Xinhua Wang & Jiuhong Kang. (2011) VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Molecular and Cellular Biochemistry 361:1-2, pages 39-45.
Crossref
Crossref
J Chang, D S Varghese, M C Gillam, M Peyton, B Modi, R L Schiltz, L Girard & E D Martinez. (2011) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. British Journal of Cancer 106:1, pages 116-125.
Crossref
Crossref
Dhanasekaran Karthigeyan, Sallekoppal B. Benaka Prasad, Jayasha Shandilya, Shipra Agrawal & Tapas K. Kundu. (2011) Biology of Aurora A kinase: Implications in cancer manifestation and therapy. Medicinal Research Reviews 31:5, pages 757-793.
Crossref
Crossref
Liya Zhang & Shulan Zhang. (2011) ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. Journal of Obstetrics and Gynaecology Research 37:6, pages 591-600.
Crossref
Crossref
Anat Biran, Michael Brownstein, Ronit Haklai & Yoel Kloog. (2010) Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy. International Journal of Cancer 128:3, pages 691-701.
Crossref
Crossref
Shaoteng Han, Takuya Fukazawa, Tomoki Yamatsuji, Junji Matsuoka, Hiroyuki Miyachi, Yutaka Maeda, Mary Durbin & Yoshio Naomoto. (2010) Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids. PLoS ONE 5:11, pages e13834.
Crossref
Crossref
Melissa J LaBonte, Peter M Wilson, William Fazzone, Susan Groshen, Heinz-Josef Lenz & Robert D Ladner. (2009) DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Medical Genomics 2:1.
Crossref
Crossref
Anne Monks, Curtis D. Hose, Patrick Pezzoli, Sudhir Kondapaka, Gordon Vansant, Kamille Dumong Petersen, Maxwell Sehested, Joseph Monforte & Robert H. Shoemaker. (2009) Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anti-Cancer Drugs 20:8, pages 682-692.
Crossref
Crossref
Ahlame Saidi, Martin Hagedorn, Nathalie Allain, Chiara Verpelli, Carlo Sala, Lorenzo Bello, Andreas Bikfalvi & Sophie Javerzat. (2009) Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. International Journal of Cancer 125:5, pages 1054-1064.
Crossref
Crossref
P.A. Marks & W.‐S. Xu. (2009) Histone deacetylase inhibitors: Potential in cancer therapy. Journal of Cellular Biochemistry 107:4, pages 600-608.
Crossref
Crossref
David S. Schrump. (2009) Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications. Clinical Cancer Research 15:12, pages 3947-3957.
Crossref
Crossref